Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $205.00 short put and a strike $200.00 long put offers a potential 24.38% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $205.00 by expiration. The full premium credit of $0.98 would be kept by the premium seller. The risk of $4.02 would be incurred if the stock dropped below the $200.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 57.03 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Better Buy: Amgen vs. Celgene
Sun, 08 Sep 2019 13:00:00 +0000
Which stock wins in a battle between these two big biotechs?
Amgen drug shrinks lung cancer tumors in half of patients -study
Sun, 08 Sep 2019 07:45:00 +0000
An experimental Amgen Inc drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial, the company said on Sunday. Out of 13 lung cancer patients taking a 960-milligram dose of AMG510, seven had tumors shrink by at least 30%, according to data presented in Barcelona at the World Conference on Lung Cancer. Cancer was stabilized in the other six high-dose patients.
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
Sun, 08 Sep 2019 07:45:00 +0000
THOUSAND OAKS, Calif., Sept. 8, 2019 /PRNewswire/ — Amgen (AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. The additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumor activity with no dose-limiting toxicities. These data are being presented during an oral presentation at IASLC 2019 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer.
Bad News Keeps Piling Up For Alexion's Soliris — But Shares Just Rallied
Fri, 06 Sep 2019 20:48:53 +0000
Alexion Pharmaceuticals stock rebounded from earlier premarket losses Friday despite a patent decision from European officials that could lead to a Soliris knockoff as early as 2021.
Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy
Fri, 06 Sep 2019 19:06:00 +0000
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
Also on Market Tamer…
Follow Us on Facebook